Biodegradable chitosan-based composites with dual functions acting as the bone scaffold and the inflammation inhibitor in the treatment of bone defects
Source abstract
Abstract
A composite based on nano-hydroxyapatite (n-HA)/chitosan (CS) and loaded with ciprofloxacin (CIP) was prepared and its physicochemical properties, antibacterial properties, drug release ability, and bone regeneration ability were characterized. The physicochemical results indicated that the n-HA/CS composite exhibited about a 70/30 ratio of n-HA to CS, and the size of n-HA in the n-HA/CS composite was about 100 nm. According to the results of the antibacterial test, the materials loaded with CIP presented excellent antibacterial activity. In addition, the in vivo concentration of CIP far surpassed the minimum inhibitory concentration (0.25–2 µg mL−1). In vitro standard deviation-rats marrow mesenchymal stem cells (MSCs) tests, including cell counting kit-8 assay and scanning electron microscopy images of MSCs, revealed that both of the scaffolds could support MSCs proliferation and attachment. The in vivo results indicated that n-HA/CS-CIP could promote the formation of bone tissues and blood vessels, and displayed a better repair ability for bone defect than the control group of n-HA-CIP. The CS-based composite with dual functions has a good perspective which would justify further research.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Graphene and Nanomaterials Applications · Orthopaedic implants and arthroplasty
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Analytical and Testing Center, Sichuan University, Chengdu, China
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China
Funding
Department of Science and Technology of Sichuan Province · National Natural Science Foundation of China · Provincial Academic and Technical Leaders Foundation of Sichuan Province
References (43)
Show source-provided references
1. 10.1097/BRS.0b013e31815cde3e10.1097/BRS.0b013e31815cde3e ↗
2. Hatzenbuehler J. · Am. Fam. Physician · 2011 · 84 · 1027
3. 10.1016/j.msec.2016.07.01110.1016/j.msec.2016.07.011 ↗
4. 10.1016/j.msec.2016.04.06210.1016/j.msec.2016.04.062 ↗
5. Willenegger H. · Der Chirurg · 1970 · 41 · 215
6. Buchholz H. W. · Der Chirurg · 1970 · 41 · 511
7. Klemm K. W. · Clin. Orthop. Relat. Res. · 1993 · 295 · 6310.1097/00003086-199310000-00011 ↗
8. Aoki, H.Science and Medical Application of Hydroxyapatite; Japanese Association of Apatite Science, Takayama Press System Center Co.: Tokyo, 1991; p. 13.
9. 10.1021/cen-v075n034.p02710.1021/cen-v075n034.p027 ↗
10. 10.1177/107110071560319110.1177/1071100715603191 ↗
11. 10.1007/s11999-015-4312-z10.1007/s11999-015-4312-z ↗
12. 10.1016/j.msec.2016.03.04010.1016/j.msec.2016.03.040 ↗
13. 10.1002/stem.229610.1002/stem.2296 ↗
14. 10.1016/j.msec.2016.05.10410.1016/j.msec.2016.05.104 ↗
15. 10.1128/AAC.00080-1610.1128/AAC.00080-16 ↗
16. 10.1002/APP.4434110.1002/APP.44341 ↗
17. 10.1016/j.carbpol.2016.09.00110.1016/j.carbpol.2016.09.001 ↗
18. 10.1080/00914037.2016.118291310.1080/00914037.2016.1182913 ↗
19. 10.1021/bm900623j10.1021/bm900623j ↗
20. 10.1016/j.fm.2016.05.00710.1016/j.fm.2016.05.007 ↗
21. Wang Y. P. · In vitro study on the degradation of lithium-doped hydroxyapatite for bone tissue engineering scaffold. Mater. Sci. Eng. C · 2016 · 66 · 185
22. 10.1016/j.msec.2016.04.10610.1016/j.msec.2016.04.106 ↗
23. 10.1016/j.colsurfb.2016.05.07810.1016/j.colsurfb.2016.05.078 ↗
24. Abdel-Aziz A. A. M. · J. Enzym. Inhib. Med. Chem. · 2015 · 31 · 1
25. 10.1021/acsami.5b0732710.1021/acsami.5b07327 ↗
26. Zhang L. · In vitro and in vivo evaluation on the bioactivity of ZnO containing nano-hydroxyapatite/chitosan cement. J. Biomed. Mater. Res. A · 2010 · 93 · 269
27. 10.1016/j.jhazmat.2015.10.01210.1016/j.jhazmat.2015.10.012 ↗
28. 10.3390/molecules2104041110.3390/molecules21040411 ↗
29. 10.1021/acs.est.5b0285110.1021/acs.est.5b02851 ↗
30. 10.1021/acs.molpharmaceut.5b0054310.1021/acs.molpharmaceut.5b00543 ↗
31. 10.3724/SP.J.1077.2009.0026410.3724/SP.J.1077.2009.00264 ↗
32. 10.1016/j.ijbiomac.2016.02.05410.1016/j.ijbiomac.2016.02.054 ↗
33. 10.1166/jnn.2016.1376310.1166/jnn.2016.13763 ↗
34. Al-Mustafa J. · Acta. Chim. Slov. · 2002 · 49 · 457
35. 10.1111/j.1365-2672.2004.02234.x10.1111/j.1365-2672.2004.02234.x ↗
36. 10.1016/j.watres.2006.08.00410.1016/j.watres.2006.08.004 ↗
37. 10.1111/j.1574-6968.2007.01012.x10.1111/j.1574-6968.2007.01012.x ↗
38. 10.1021/la703594910.1021/la7035949 ↗
39. 10.1016/S0167-7012(03)00037-X10.1016/S0167-7012(03)00037-X ↗
40. 10.1186/s11671-015-1047-410.1186/s11671-015-1047-4 ↗
41. 10.1016/j.msec.2016.12.06010.1016/j.msec.2016.12.060 ↗
42. 10.3390/ma1003022910.3390/ma10030229 ↗
43. 10.1016/0378-5173(89)90306-210.1016/0378-5173(89)90306-2 ↗